ModifiedUnitedHealthcarePolicy CS031PA.R

Discogenic Pain Treatment (for Pennsylvania Only)

Medical policy governing coverage and medical necessity determinations for procedures to treat discogenic low back pain in Pennsylvania, affecting providers requesting these services for UnitedHealthcare members in that state.

Policy Summary

PayerUnitedHealthcare

PolicyDiscogenic Pain Treatment (for Pennsylvania Only)

Policy CodePolicy CS031PA.R

Change TypeCoding updateevidence/reference updates

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization with documentation of prior conservative management and indication when requesting intradiscal biologics or thermal intradiscal procedures.

SourceLink

POLICY UPDATE CHANGES

Updated list of applicable CPT codes to reflect annual edits; added 63032.

Updated Clinical Evidence and References sections to reflect the most current information.

3procedures listed as unproven / not medically necessary

0627T-0630T, 22526-22527, 22899, 63032, S2348sample CPT/HCPCS codes referenced

≥6 mmannular defect size referenced

931patients treated with ACD in ISASS evidence

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

limitation frequently noted

Coverage and Clinical Determinations

Not medically necessary / Unproven procedures

The following procedures are considered unproven and not medically necessary due to insufficient evidence of efficacy:

Listed procedures: Annular closure devices (ACDs); Percutaneous injection of allogeneic cellular/tissue-based products; Thermal intradiscal procedures (TIPs)

These three categories are explicitly listed as unproven/not medically necessary in the policy.

Annular Closure Devices (ACDs)

Evidence summary and selection factors observed in trials:

ACD trial selection and outcomes: Trials enrolled patients with large post-discectomy annular defects (typically ≥ 6 mm) and other favorable characteristics (adequate disc height, non-osteoporotic BMD); randomized data (Thomé et al.) reported reduced recurrent herniation and reoperation with a bone-anchored ACD versus microdiscectomy alone, but study limitations include lack of masking, potential conflicts of interest, single-sponsor influence, retrospective analyses, and small or overlapping study populations.Annular defect typically ≥ 6 mm

ACD outcomes: reduced reherniation and reoperation reported (e.g., 5% vs 13% reoperation in Thomé 2018); vertebral endplate changes increased with ACD though clinical outcomes comparable in some analyses.

Percutaneous injection of allogeneic cellular/tissue-based products

Evidence and limitations for percutaneous intradiscal allogeneic cellular/tissue-based products:

Intradiscal allograft evidence: Available evidence includes small randomized trial(s) and single-arm feasibility studies with mixed results; systematic assessments (Hayes, ECRI) conclude insufficient high-quality evidence to determine superiority over placebo or nonsurgical management, citing small sample sizes, methodological limitations, loss to follow-up, and need for independent replication and larger RCTs.

Beall et al. RCT did not show clear benefit vs saline for primary outcomes at 12 months; feasibility studies report improvements but lack comparators.

Thermal Intradiscal Procedures (TIPs)

Evidence summary for IDET, IDB, PIRFT and related procedures:

TIPs evidence: Evidence is variable: some RCTs and systematic reviews report benefit for biacuplasty and mixed support for IDET, while other RCTs (e.g., PIRFT discTRODE) showed no benefit over sham. Many studies are single-center, nonrandomized, or small; overall quality is limited and additional larger, well-controlled RCTs with longer follow-up are needed.

Helm systematic review identified Level I evidence for biacuplasty (based on two RCTs) and lower-level evidence for IDET; trials frequently lack sham controls and have risk of bias.

Percutaneous intradiscal thermal procedures (PIRFT, intradiscal electrothermal therapy, bipolar RFTC, L'DISQ, biacuplasty)

Coverage stance based on available evidence and guideline recommendations

Evidence summary: Randomized and controlled trials show inconsistent or no clear benefit of PIRFT and similar intradiscal thermal therapies versus sham or conservative care; systematic reviews and guideline bodies (NICE, NASS, ASIPP) characterize the evidence as limited, inconsistent, or insufficient to recommend routine use.

Kvarstein et al. (PIRFT RCT) found no benefit over sham at 6 months and no significant difference at 12 months; NICE and NASS note limited/inconsistent evidence and encourage further research.

Annular closure device (Barricaid) following primary discectomy

Coverage stance for bone-anchored annular closure after lumbar discectomy in selected patients

Indication and evidence: Evidence from randomized trials, observational studies, and FDA premarket approval indicate that a bone-anchored annular closure device (Barricaid) reduces symptomatic recurrent lumbar disc herniation and reoperation in selected patients undergoing primary discectomy with large annular defects; FDA approval specifies skeletally mature patients, single-level L4–S1, and annular defect dimensions of 4–6 mm tall by 6–10 mm wide.Annular defect 4-6 mm tall and 6-10 mm wide; single level L4–S1; skeletally mature

ISASS and multiple analyses report reduced reherniation/reoperation; device has FDA PMA K201676 indicating the approved indication and measurement requirements.

The policy considers several intradiscal interventions to be unproven and not medically necessary because available evidence does not demonstrate consistent clinical benefit. Specifically, annular closure devices (ACDs), percutaneous injection of allogeneic cellular/tissue-based products, and thermal intradiscal procedures (TIPs) are identified as lacking sufficient high-quality evidence to support routine use for discogenic low back pain. Requests for these procedures may be denied when submitted as medically necessary interventions for discogenic pain.

Percutaneous injection of donor-derived cellular or tissue products into the intervertebral disc is regarded as investigational due to insufficient high-quality evidence. The policy notes that current studies are limited by small sample sizes, methodological weaknesses, and lack of long-term outcomes; robust randomized controlled trials with larger populations and longer follow-up are required to establish safety and efficacy before these intradiscal allogeneic injections can be considered medically necessary.

Percutaneous intradiscal thermal therapies—including intradiscal electrothermal therapy (IDET), intradiscal biacuplasty (IDB), PIRFT and related radiofrequency/thermal techniques—are not supported by consistent, high-quality evidence. Systematic reviews and guideline assessments conclude that the evidence is limited and inconsistent, and randomized trials (for example, PIRFT with the discTRODE probe) have not demonstrated clear benefit versus sham. Consequently, routine use of PIRFT and similar intradiscal thermal procedures is discouraged pending more rigorous trials and longer-term data.

Summarizing the coverage stance: annular closure devices, percutaneous allogeneic intradiscal injections, and thermal intradiscal procedures are considered unproven and not medically necessary for the treatment of discogenic low back pain based on current evidence. Absent stronger, reproducible randomized controlled trial data demonstrating clinically meaningful benefit and acceptable long-term safety, these categories are excluded from coverage.

The policy specifically identifies percutaneous intradiscal use of allogeneic cellular/tissue-based products and broadly described thermal intradiscal procedures as not supported by sufficient evidence. For these approaches the document emphasizes the need for well-designed randomized trials, larger patient cohorts, and longer follow-up before they can be recommended or considered medically necessary for discogenic pain management.

A double-blind, placebo-controlled RCT of PIRFT using the discTRODE probe (Kvarstein et al.) enrolled 20 patients and was terminated for futility after a 6‑month blinded interim analysis because there was no trend toward benefit over sham for the primary pain outcome. At 12 months both groups showed some reduction from baseline but no significant between-group differences; the study authors concluded they would not recommend intra‑annular thermal therapy with the discTRODE probe given these results.

Coding and Billing References

Allogeneic cellular/tissue-based injection codesCPT

0627T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level.
0628T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure).
0629T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level.

Thermal intradiscal, ACD and related codesCPT|HCPCS

0630T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure).
22526	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level.
22527	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure).
22899	Unlisted procedure, spine.
63032	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; with repair of annular defect by implantation of bone-anchored annular closure device, including all imaging guidance, 1 interspace, lumbar (List separately in addition to code for primary procedure)
S2348	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar

Applicable CPT Codes (updated)CPT

63032

Added CPT code per annual edits (as referenced in Policy History).

FDA product codes (informational)mixed

Product code: FTL	surgical mesh, polymeric (FDA product code for annulus closure related devices)
Product code: FTM	mesh, surgical (FDA product code)
Product code: GAT	suture, nonabsorbable, synthetic, polyethylene (FDA product code)

Annular defect size for ACD studies — typical threshold

Typical annular defect size used in ACD studiesTypically ≥ 6 mm

Study inclusion contextPatients often had symptomatic radiculopathy and large post-discectomy annular defects (e.g., 6–10 mm width in Thomé et al.)

Conservative care prior to enrollment> 6 weeks of failed conservative management in most included studies

Annular defect dimensions for Barricaid (FDA indication)

FDA-specified annular defect height4–6 mm tall

FDA-specified annular defect width

Provider Requirements, Prior Authorization, and Documentation

Billing Rule

Codes referenced for review — inclusion does not imply coverage

Codes listed in this policy are provided for reference only and do not by themselves determine coverage or payment. Inclusion of a code does not imply that the service is covered. Prior authorization and adjudication are subject to federal, state, and contractual requirements.

Affected codes referenced in policy include: 0627T, 0628T, 0629T and other procedure codes listed in the Applicable Codes section. CPT code 63032 was added in the 2026-04-01 update.

Prior Authorization

Prior authorization recommended for intradiscal biologics and TIPs

Prior authorization is recommended for intradiscal biologic injections (percutaneous allogeneic cellular/tissue-based products) and thermal intradiscal procedures (TIPs). Requests should document prior conservative management and a clear clinical indication consistent with trial populations. Absent sufficient supporting documentation or when evidence is insufficient, requests may be denied.

Conservative Care and Prior Treatment Thresholds

Failure of conservative care in many included studies prior to surgical intervention

Failure of conservative care documented in many included studies prior to surgical intervention:

Study populations: Many ACD and related studies enrolled patients who had failed more than six weeks of conservative care or had contraindications to conservative treatment; this duration is commonly noted in trial entry criteria.> 6 weeks

Hayes assessment and included trials described prior failure of conservative care >6 weeks in most cases.

Document failure of conservative care (physical therapy, medications, interventional procedures, lifestyle measures) prior to invasive intradiscal interventions

Document failure of conservative care prior to invasive intradiscal interventions:

Conservative care requirement: Prior to consideration of invasive intradiscal procedures (e.g., IDET, IDB, intradiscal biologics), document inadequate response to at least three months of conservative management, which may include physical therapy, medications, interventional procedures, and lifestyle measures.

Imaging and Diagnostic Evidence

Billing Rule

Imaging guidance required (fluoroscopy or CT) for TIPs and injections

Thermal intradiscal procedures and most percutaneous intradiscal injections require imaging guidance—procedures are performed under fluoroscopy or CT depending on the code and technique.

Policy descriptions specify fluoroscopic guidance for TIPs and some injection codes specify CT guidance

Documentation Required

Document MRI (HIZ) and/or discography findings for IDET/IDB eligibility

Many IDET/IDB and related study inclusion criteria required MRI findings (e.g., high-intensity zone) and/or provocation discography results; document these imaging findings when applicable.

Record MRI HIZ status, discography DDS grade, and preserved disc height if used to justify the procedure

Documentation Required

Key Definitions and Device Names

Annular closure device (ACD) — implantable device definition

DefinitionImplantable device intended to reinforce or bridge an annulus fibrosus defect created by discectomy to prevent nucleus material reherniation and reduce recurrent herniation/reoperation.

Typical usePlaced at time of limited lumbar microdiscectomy for large annular defects.

Evidence contextRCTs report reduced recurrent herniation and reoperation but overall evidence quality is limited by study design and potential conflicts of interest.

Thermal intradiscal procedures (TIPs) — percutaneous procedures definition

DefinitionPercutaneous procedures that insert a catheter or probe into the disc under imaging guidance to apply heat or radiofrequency energy to denature collagen, ablate nociceptors, or alter disc biomechanics.

Included procedures

Procedure Frequency and Repeat Interventions

PIRFT / intradiscal thermal therapies — frequency limit / status

StatusNot specified as a formal frequency limit in the policy; PIRFT and related intradiscal thermal therapies are listed as unproven/not medically necessary due to insufficient evidence.

Evidence implicationRandomized trial (discTRODE) found no benefit over sham at 6 months and no significant difference at 12 months; this supports non‑coverage or denial risk rather than an allowance-based frequency limit.

Provider actionPrior authorization is recommended and documentation of prior conservative management and clear indication is expected when these procedures are requested.

Explicit Non‑Coverage Statements

Not covered: Annular closure devices (ACDs); percutaneous injection of allogeneic cellular/tissue-based products into the intervertebral disc; and thermal intradiscal procedures (IDET, IDB/biacuplasty, PIRFT and similar thermal therapies) are listed as unproven and therefore not medically necessary for treatment of discogenic low back pain.

Not covered: Percutaneous intradiscal allogeneic cellular/tissue-based products and unspecified thermal intradiscal procedures are considered to have insufficient high-quality evidence to establish safety and effectiveness; coverage is not supported at this time.

Not covered: Routine use of PIRFT and comparable intradiscal thermal procedures is not supported by current evidence. Randomized and controlled data are inconsistent or negative, and these procedures are therefore not considered medically necessary for routine management of discogenic pain.

Not covered: Annular closure devices are included among the procedures deemed unproven and not medically necessary for treating discogenic low back pain, except as described elsewhere in the policy for device-specific indications with required documentation.

Not covered: Percutaneous injection of allogeneic cellular/tissue-based products into the intervertebral disc is considered investigational and not medically necessary due to lack of sufficient high-quality evidence.

Not covered: Routine use of PIRFT and similar intradiscal thermal procedures is not supported. Guideline assessments (for example NICE) describe the evidence as limited and inconsistent, and randomized data such as the discTRODE PIRFT trial failed to show benefit versus sham, supporting the policy’s noncoverage stance for these thermal procedures.

Clinical Background and Evidence Summary

Background: Discogenic low back pain arises from degeneration or internal disruption of the intervertebral disc and may present as axial low back pain with or without radicular symptoms. Interventional approaches proposed to address discogenic pain include annular closure devices to bridge or reinforce post‑discectomy annular defects, thermal intradiscal procedures (TIPs) that apply heat or radiofrequency energy to denervate or alter disc tissue, and percutaneous allogeneic cellular/tissue-based injections intended to replace or regenerate disc tissue. Current evidence for these interventions is limited or inconsistent, which underlies the policy’s conservative coverage stance.

Policy Summary

PayerUnitedHealthcare

PolicyDiscogenic Pain Treatment (for Pennsylvania Only)

Policy CodePolicy CS031PA.R

Change TypeCoding updateevidence/reference updates

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization with documentation of prior conservative management and indication when requesting intradiscal biologics or thermal intradiscal procedures.

SourceLink

On This Page

Device-level limitationIndication applies after primary discectomy at a single level between L4 and S1 in skeletally mature patients

Require documentation of prior conservative management (e.g., physical therapy, pharmacologic management, interventional procedures) and duration of symptoms.
Clinical rationale and imaging confirming discogenic pain should be provided.
Prior authorization may be required per plan and state rules.

Denial Risk

Evidence insufficiency may trigger denial

The evidence base for percutaneous allogeneic injections and many thermal intradiscal procedures is limited or inconsistent. Insufficient high‑quality evidence may trigger denial of requests for these procedures.

Insufficient RCT data, small sample sizes, and limited long-term outcomes are key evidence gaps.
Requests lacking robust supportive clinical evidence or appropriate conservative-treatment documentation are at higher risk for denial.

Denial Risk

PIRFT randomized trial outcomes — no benefit over sham at 6 months

A randomized, double‑blind placebo RCT of PIRFT (discTRODE) found no benefit over sham at 6 months; at 12 months pain reductions occurred but without significant difference between groups. This trial did not support PIRFT efficacy and is a basis for noncoverage of PIRFT procedures.

PIRFT trial stopped early for lack of benefit at 6 months; no significant difference versus sham at 12 months.
High rates of increased pain and limited evidence led authors to not recommend intra‑annular thermal therapy with the discTRODE probe.

Note

State-specific adjudication note — Pennsylvania exceptions/PARP case-by-case evaluation

This Medical Policy applies to Pennsylvania only. Requests that do not meet PARP criteria will be evaluated on a case‑by‑case basis per Pennsylvania Exceptions (PA Code, Title 55, Chapter 1101).

Refer to Pennsylvania Exceptions, Pennsylvania Code, Title 55, Chapter 1101 for adjudication exceptions and PARP procedures.

Documentation Required

Clinical selection and shared decision-making documentation

When procedures such as annular closure devices (Barricaid) or other intradiscal interventions are considered, document clinical selection and shared decision‑making. Selection criteria should mirror trial populations when applicable (e.g., symptom duration, imaging confirmation, annular defect size) and include discussion of risks, benefits, and alternative therapies.

Document duration of symptoms and prior conservative management (e.g., >6 weeks where applicable).
Provide imaging and clinical findings that match device indications (e.g., annular defect size and neural compression where relevant).
Record shared decision‑making discussion and consent addressing uncertain long‑term benefits and potential risks.

Documentation Required

Barricaid device documentation

For Barricaid (an FDA‑approved annular closure device), include specific documentation per device indication: patient must be skeletally mature with radiculopathy attributed to a posterior or posterolateral herniation, imaging demonstrating neural compression, and a qualifying large annular defect (4–6 mm tall and 6–10 mm wide) following a single‑level primary discectomy between L4 and S1. Provide operative notes and imaging to support these criteria.

Confirm skeletal maturity and single‑level L4–S1 primary discectomy.
Document annular defect dimensions and MRI evidence of neural compression.
Supply operative report and pre/postoperative imaging with the authorization request.

Prior Authorization

Require prior conservative management — document CMM prior to invasive intradiscal interventions

Conservative medical management (CMM) is expected and served as the comparator in randomized trials of intradiscal procedures. Documentation of adequate trial(s) of CMM (e.g., physical therapy, medications, interventional injections, and lifestyle measures) should be provided prior to invasive intradiscal interventions.

Document duration and components of conservative care, and response to those measures.
If crossover from CMM to intervention occurred in trials, note that lack of sham comparisons limits interpretation.

Several studies and RCTs required ≥3 months of conservative therapy and used conventional medical management as the comparator.

Document prior conservative management and detailed patient selection where applicable

Operational requirement for documentation of prior management and patient selection:

Documentation and selection: When requesting coverage for intradiscal interventions or device implantation, provide detailed documentation of prior conservative management, imaging and diagnostic findings (e.g., MRI, discography, HIZ), and patient selection criteria consistent with published trials; include shared decision-making notes where applicable.

NICE and trial reports emphasize clear documentation of patient selection, symptom duration, and technique; RCTs often required imaging-confirmed degeneration and provocation testing.

MRI usually required for ACD (Barricaid) patient selection

Annular closure device placement after discectomy typically requires MRI to document neural compression and support device indication; document imaging and anatomical measurements per the FDA indication.

MRI demonstrating neural compression and annular defect measurements consistent with FDA labeling should be in the record

Examples include intradiscal electrothermal therapy (IDET), intradiscal biacuplasty (IDB/biacuplasty), and percutaneous intradiscal radiofrequency thermocoagulation (PIRFT).

GuidanceProcedures are performed under fluoroscopic (or sometimes CT) guidance.

Percutaneous allogeneic cellular/tissue-based injection — definition

DefinitionPercutaneous injection of donor-derived (allogeneic) cellular or tissue products into the intervertebral disc intended to stimulate tissue repair or replace/supplement nucleus pulposus.

Product exampleViable disc allograft (e.g., VIADISC NP / Via Disc NP) delivered intradiscally in feasibility studies and RCTs.

Evidence noteAvailable evidence is limited (small RCTs, single-arm studies); further robust RCTs are required to establish safety and efficacy.

Annular Closure Device (ACD) — bone‑anchored implant definition and intent

DefinitionA bone‑anchored implant placed at the time of limited lumbar microdiscectomy designed to close large annular defects and reduce recurrent herniation and reoperation.

Intended effectReduce symptomatic recurrent lumbar disc herniation and need for reoperation in selected patients with large defects.

Patient selectionUsed in patients with large post‑discectomy annular defects and specific favorable characteristics (adequate disc height, skeletally mature, non‑osteoporotic BMD).

Intradiscal allogeneic cellular/tissue-based product (Via Disc NP / VIADISC NP) — definition

DefinitionA percutaneously injected viable disc allograft (nucleus pulposus) product intended to treat degenerative disc disease by replacing or supplementing disc material.

Commercial exampleVIADISC NP / Via Disc NP allograft evaluated in randomized and feasibility studies.

Study limitationsTrials and feasibility studies are small, sometimes industry‑sponsored, with heterogeneity in levels treated and follow‑up duration.

Thermal intradiscal procedures (TIPs) — consolidated definition

Consolidated definitionProcedures that apply heat or radiofrequency energy intradiscally via a catheter or probe under imaging guidance to denature collagen, lesion nociceptors, or otherwise alter disc biomechanics to relieve discogenic low back pain.

ExamplesIntradiscal electrothermal therapy (IDET), intradiscal biacuplasty (IDB/biacuplasty), bipolar RFTC, L'DISQ, and percutaneous intradiscal radiofrequency thermocoagulation (PIRFT).

Evidence summaryEvidence quality is variable: some RCTs support biacuplasty; IDET evidence is mixed; PIRFT trials have shown no benefit over sham in at least one RCT.

PIRFT definition — percutaneous intra‑annular radiofrequency thermal therapy

DefinitionPercutaneous intra‑annular radiofrequency thermal therapy that places an RF probe into the center of the disc to apply thermal energy (e.g., 70°C for 90 seconds) intended to modulate annulus/nucleus and reduce discogenic pain.

Also known asIntradiscal electrothermal annuloplasty (IEA), intradiscal radiofrequency thermomodulation, RF annuloplasty, or radiofrequency posterior annuloplasty.

Evidence noteA double‑blind RCT (discTRODE) found no benefit over sham at 6 months and no significant difference at 12 months, leading to a recommendation against intra‑annular thermal therapy with the discTRODE probe by study authors.

Barricaid Annular Closure Device — FDA‑approved implant indication summary

FDA approval summaryBarricaid received FDA premarket approval (PMA K201676) on Feb 8, 2019 for reducing reherniation and reoperation after primary discectomy in skeletally mature patients with large annular defects.

Indication specificsIndicated for symptomatic radiculopathy with MRI‑confirmed neural compression and annular defect dimensions between 4–6 mm tall and 6–10 mm wide at a single level L4–S1 after primary discectomy.

Clinical evidenceRCTs (e.g., Thomé et al.) report reduced recurrent herniation and reoperation with bone‑anchored ACD implantation versus discectomy alone, though trials have methodological limitations.